scholarly journals Seasonal influenza vaccine dose distribution in 157 countries (2004–2011)

Vaccine ◽  
2014 ◽  
Vol 32 (48) ◽  
pp. 6369-6376 ◽  
Author(s):  
Abraham Palache ◽  
Valerie Oriol-Mathieu ◽  
Atika Abelin ◽  
Tamara Music
Keyword(s):  
Influenza Vaccine ◽  
Dose Distribution ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Seasonal Influenza Vaccine

scholarly journals Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): Little progress in estimated global vaccination coverage

Vaccine ◽  
2015 ◽  
Vol 33 (42) ◽  
pp. 5598-5605 ◽  
Author(s):  
Abraham Palache ◽  
Valerie Oriol-Mathieu ◽  
Mireli Fino ◽  
Margarita Xydia-Charmanta
Keyword(s):  
Influenza Vaccine ◽  
Vaccination Coverage ◽  
Dose Distribution ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Seasonal Influenza Vaccine

scholarly journals Trends in seasonal influenza vaccine distribution in the European Union: 2003-4 to 2007-8

2008 ◽  
Vol 13 (43) ◽  
Author(s):  
M Rodríguez de Azero ◽  
Collective the European Vaccine Manufacturers Influenza Working Group
Keyword(s):  
Public Health ◽  
Influenza Vaccine ◽  
Dose Distribution ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Risk Groups ◽  
Vaccine Uptake ◽  
World Health ◽  
Distribution Data ◽  
Vaccine Distribution

Seasonal influenza is widely regarded as a continuing threat to public health, with vaccination remaining the principal measure of prophylaxis. In 2003, the World Health Organization issued targets for influenza vaccine coverage in the elderly of at least 50% by 2006 and 75% by 2010, endorsed by the European Parliament in two resolutions in 2005 and 2006. However, a number of European public health systems lack mechanisms to assess progress in influenza vaccine uptake. The European Vaccine Manufacturers group (EVM) undertook a Europe-wide survey of vaccine distribution over the last five seasons (between 2003 and 2008) to provide baseline data from which vaccination trends may be extrapolated. The survey data showed that the dose distribution level per capita in the 27 EU countries increased from 17% in 2003-4 to 20% in 2006-7; this growth was not maintained in the season 2007-8. Even without information on which age or risk groups received the vaccine, an immunisation rate of approximately 20% of the whole population falls short of the public health goal by more than half: an estimated 49% of the total population fall into risk groups recommended to receive the influenza vaccine in Europe. These data provide the only systematic review of vaccine dose distribution across Europe from a uniform source. Although they represent an important baseline parameter, age- and risk-group related vaccine uptake data with sufficient detail are needed to assist public health policy decision making, immunisation planning and monitoring. In light of this situation, and to support the improvement of immunisation rates across the EU, EVM aims to provide dose distribution data for each influenza season to assist Member States in the implementation of local immunisation policies.

scholarly journals Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

2014 ◽  
Vol 8 (09) ◽  
pp. 1160-1168 ◽  
Author(s):  
Adib Rodriguez Solares ◽  
Carlos Grazioso Aragon ◽  
Rodolfo Urruela Pivaral ◽  
David Prado-Cohrs ◽  
Victor Sales-Carmona ◽  
...  
Keyword(s):  
Adverse Events ◽  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Antibody Responses ◽  
Entire Study ◽  
Seasonal Influenza Vaccine ◽  
Adjuvanted Vaccine ◽  
Trivalent Influenza Vaccine ◽  
Antibody Titers

Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal.  This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non-adjuvanted, trivalent, influenza vaccine (TIV) in Guatemalan children (N = 360) between 6 and < 60 months of age. Methodology: Children received two doses of ATIV or TIV administered four weeks apart. Solicited adverse reactions were recorded for seven days after each vaccination. Serious adverse events were recorded throughout the entire study period. Antibody responses were assessed by hemagglutination inhibition (HI) assay at baseline, four weeks after administration of the first vaccine dose, and three weeks after administration of the second dose. Results: Both ATIV and TIV were well tolerated, with similar rates of solicited reactions and adverse events observed in response to both vaccines. MF59-adjuvanted vaccine induced considerably higher antibody titers than did TIV. After two doses, the B strain-specific antibody response to TIV was insufficient to meet the Center for Biologics Evaluation and Research (CBER) licensure criterion for seroprotection, whereas responses to the MF59-adjuvanted vaccine met the seroprotection criterion against all three strains. Cross-reactive antibody responses to MF59-adjuvanted vaccine met the CBER seroprotection criterion against all three strains after two doses; B strain-specific heterologous responses to non-adjuvanted TIV were inadequate. Conclusions: The MF59-adjuvanted seasonal influenza vaccine was well-tolerated and highly immunogenic in children 6 to < 60 months of age, inducing seroprotective antibody titers against both the vaccine strains and antigenically distinct heterologous strains.

scholarly journals Healthcare Workers’ Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 465
Author(s):  
Leena R. Baghdadi ◽  
Shatha G. Alghaihb ◽  
Alanoud A. Abuhaimed ◽  
Dania M. Alkelabi ◽  
Rawan S. Alqahtani
Keyword(s):  
Saudi Arabia ◽  
Influenza Vaccine ◽  
Work Experience ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Seasonal Influenza Vaccine ◽  
History Of

In 2019, a novel severe acute respiratory syndrome (SARS-CoV-2 (COVID-19)) caused a global pandemic. There was an urgent need to develop a vaccine against COVID-19 to reduce its spread and economic burden. The main objective of this study was to understand the attitudes and concerns of healthcare workers (HCWs) towards the upcoming COVID-19 vaccine, whether their decision was influenced by their history of taking the seasonal influenza vaccine, and factors that influence the acceptance of the upcoming COVID-19 vaccine. This was a cross-sectional study conducted in Riyadh, Saudi Arabia. We selected and surveyed 356 HCWs via an electronic self-administered questionnaire. A total of 61.16% of HCWs were willing to receive the COVID-19 vaccine, and 55.9% of them had received the seasonal influenza vaccine in the preceding year (2019–2020). The strongest predictors for taking the COVID-19 vaccine were the HCWs’ belief that the COVID-19 vaccine would be safe, needed even for healthy people, that all HCWs should be vaccinated against COVID-19, and that HCWs will have time to take the vaccine. Being female, being middle aged, having <5 years of work experience, having no fear of injections, and being a non-smoker were predictive factors for taking the upcoming COVID-19 vaccine. No associations were found between the intention to take the COVID-19 vaccine and a history of taking the seasonal influenza vaccine.

scholarly journals Mapping the inequality of the global distribution of seasonal influenza vaccine

2021 ◽  
pp. 0308518X2199835
Author(s):  
Yen Ching Yau ◽  
Michael T Gastner
Keyword(s):  
Influenza Vaccine ◽  
Respiratory Diseases ◽  
Seasonal Influenza ◽  
Developed Countries ◽  
Essential Medicines ◽  
World Health ◽  
Equitable Access ◽  
Seasonal Influenza Vaccine ◽  
Choropleth Map ◽  
Vaccine Distribution

With an estimated annual worldwide death toll of between 290 000 and 650 000, seasonal influenza remains one of the deadliest respiratory diseases. Influenza vaccines provide moderate to high protection and have been on the World Health Organization’s Model List of Essential Medicines since 1979. Approximately 490 million doses of influenza vaccine are produced per year, but an investigation of geographic allocation reveals enormous disparities. Here, we present two maps that visualise the inequality of the distribution across 195 countries: a conventional choropleth map and a cartogram. In combination, these two maps highlight the widespread lack of coverage in Africa and many parts of Asia. As COVID-19 vaccines are now being distributed in developed countries, data for seasonal influenza vaccine distribution emphasises the need for policymakers to ensure equitable access to COVID-19 vaccines.

Sign in / Sign up

Export Citation Format

Share Document